Autologous hematopoietic stem cell transplantation for multiple sclerosis: Long-term follow-up data from Norway.

ABSTRACT:

Background

Autologous hematopoietic stem cell transplantation (HSCT) is a potent treatment option for patients with aggressive relapsing-remitting multiple sclerosis (RRMS).

Objective

To evaluate long-term outcomes of HSCT in MS.

Methods

National retrospective single-center observational study of patients with aggressive RRMS that underwent HSCT in Norway from January 2015 to January 2018. Criteria for receiving HSCT included at least two clinical relapses the last year while on disease modifying treatment (DMT).

Results

In total, 29 patients, with a mean follow-up time of 70 months (standard deviation:14.3), were evaluated. Twenty patients (69%) had sustained no evidence of disease activity (NEDA-3) status, 24 (83%) were relapse-free, 23 (79%) free of magnetic

SUBMITTER: Kvistad CE 

PROVIDER: S-EPMC11071593 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature